March 2020 Appendix 4C and Quarterly Report- Exopharm is now a...

March 2020 Appendix 4C and Quarterly Report

- Exopharm is now a clinical stage company, and the first company in the world to test a proprietary exosome product in human clinical trials, for regenerative medicine, with first dosing of PlexarisTM occurring in Exopharm's PLEXOVAL Study during the quarter
- Planning for the first-in-human allogeneic Plexaris safety study is progressing, however the PLEXOVALI study has been affected by the COVID-19 situation
- BioMAP external testing validates possible safety and mechanism of action
- Independent testing by PELVIPHARMshows potency of Cevaris in models of erectile dysfunction, and provides a basis for further testing, and future potential clinical trials in post-operative erectile dysfunction
- Positive PELVIPHARM testing provides a basis for further testing, and future potential clinical trials in urinary bladder control
- Exopharm consolidates main laboratory and manufacturing facility at the Baker Institute in Melbourne
http://exopharm.com/wp-content/uploads/2020/04/73._20.04.24-March-20-Quarterly-Reports-David-Parker.pdf